首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   2110101篇
  免费   146657篇
  国内免费   5164篇
耳鼻咽喉   30686篇
儿科学   64829篇
妇产科学   61045篇
基础医学   296560篇
口腔科学   60836篇
临床医学   178087篇
内科学   416716篇
皮肤病学   47310篇
神经病学   168359篇
特种医学   85165篇
外国民族医学   749篇
外科学   328079篇
综合类   46929篇
现状与发展   7篇
一般理论   674篇
预防医学   148587篇
眼科学   49571篇
药学   156036篇
  4篇
中国医学   4814篇
肿瘤学   116879篇
  2018年   20237篇
  2016年   18053篇
  2015年   20680篇
  2014年   28866篇
  2013年   43550篇
  2012年   57725篇
  2011年   60828篇
  2010年   36661篇
  2009年   35087篇
  2008年   57584篇
  2007年   62024篇
  2006年   62423篇
  2005年   60866篇
  2004年   58558篇
  2003年   56723篇
  2002年   55676篇
  2001年   96064篇
  2000年   98906篇
  1999年   84036篇
  1998年   23127篇
  1997年   21032篇
  1996年   20487篇
  1995年   19229篇
  1994年   18180篇
  1993年   16949篇
  1992年   65403篇
  1991年   63164篇
  1990年   61841篇
  1989年   60235篇
  1988年   56140篇
  1987年   55115篇
  1986年   52908篇
  1985年   50352篇
  1984年   37739篇
  1983年   32128篇
  1982年   19379篇
  1981年   17432篇
  1979年   35925篇
  1978年   25471篇
  1977年   22024篇
  1976年   20161篇
  1975年   22636篇
  1974年   26929篇
  1973年   25969篇
  1972年   24877篇
  1971年   23144篇
  1970年   22078篇
  1969年   21024篇
  1968年   19838篇
  1967年   18052篇
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
31.
32.
背景:Parkin基因(PRKN)突变可导致常染色体隐性遗传性早发帕金森病(EOPD)。目的:探讨EOPD白人家族PRKN突变的表现和基因型-表型关系。设计:对EOPD家族的3代20例成员进行基因分析,该家族有4例患者。应用直接基因组DNA测序、半定量聚合酶链反应、实时定量聚合酶链反应以及逆转录酶聚合酶链反应分析以确定PRKN突变。结果:4例早发患者(年龄30—38岁)被确定有PRKN复合杂合突变(T240M和EX5_6缺失),虽然PRKN的杂合T240M和纯合EX5_6缺失突变已有描述,但是据悉,本文为上述复合杂合突变的首次报道。患者的表型为典型常染色体隐性遗传性EOPD的表现,其特征是对左旋多巴治疗有效、相对缓慢的进展和运动障碍。所有杂合突变的基因携带者(T240M或EX5_6缺失)和1例56岁的复合杂合突变女性携带者(T240M和EX5_6缺失)无任何神经系统症状。结论:研究发现,PRKN基因复合杂合突变(T240M和EX5_6缺失)导致一个大的白人家族中4例成员发生常染色体隐性遗传性EOPD。另外1例成员具有相同的突变,比4例患者的平均发病年龄大10岁,并且无本病的临床表现。不完全的外显率对遗传咨询具有暗示作用,并且提示复杂的基因一环境交互作用在PRKN相关EOPD的发病机制中发挥作用。  相似文献   
33.
Low molecular weight heparins are widely used in the prophylaxis and treatment of thrombotic disorders. The effect of low molecular weight heparins on coagulation was examined ultrastructurally in an animal model. A test and a control group was formed, each consisting of five rabbits. Nadroparine (225 Institute of Chaoy Unit/kg twice daily) was applied to the test group for 10 days. The control group received 1 ml saline solution subcutaneously. Blood and vascular tissue samples collected at the end of the 10th day were evaluated under a JEM 100 B electron microscope. Platelet degranulation and agglutination was observed in the control group. Fibrin materials were detected in the cytoplasms and surroundings of degranulated platelets. Erythrocyte accumulation was remarkable on the vascular endothelium with intact coagulation periods. In the test group, outer membranes of platelets, hyalomere, and granular structures in the granulomeres were detected to be nearly intact. There were rare erythrocytes in the large vascular lumens. The aggregation phase had occurred but no agglutination was detected. Nadroparine seems to preserve consistency of lipoprotein membranes of platelets and granular structures containing enzymes, which contribute to the coagulation mechanisms.  相似文献   
34.
Summary: A female patient with isovaleric acidaemia had a successful outcome from pregnancy.  相似文献   
35.
36.
37.
38.
39.
Vitiligo and psoriasis are both common skin disorders. However, psoriasis strictly confined to pre-existing vitiligo areas is rare and suggests a causal relationship. We report here on two patients with a strict anatomical colocalization of vitiligo and psoriasis. The histopathological examinations showed typical changes for both diseases together with a dense infiltrate of CD4+ and CD8+ T cells. By immunohistochemistry, intracytoplasmatic granzyme B and tumour necrosis factor alpha (TNF-alpha) were detected within the T-cell population, suggesting the functional activity of these cells and the creation of a local T helper 1 (Th1)-cytokine milieu. Additionally, in one patient we could identify anti-melanocytic T cells by tetramer staining and enzyme-linked immunospot (ELISPOT) analysis. These skin-infiltrating lymphocytes might trigger, by the local production of Th-1 cytokines such as TNF-alpha and interferon-gamma (IFN-gamma), the eruption of psoriatic plaques in patients with a genetic predisposition for psoriasis.  相似文献   
40.
To determine if impaired energy metabolism might contribute to some aspects of Alzheimer disease (AD), including the vulnerability of the CA1 region of the hippocampal formation and the altered cytoskeleton evident in neurofibrillary tangles, we examined the effects of metabolic poisons on neuronal damage and cytoskeletal disruption in the hippocampal formation. Intrahippocampal injection of 3-nitropropionic acid (3-NP) and malonic acid resulted in neuronal death, particularly in CA1. Cytoskeletal disruption included loss of dendritic MAP2, but sparing of axonal τ. MK-801 (a noncompetitive NMDA receptor antagonist) did not atenuate the lesions produced by intrahippocampal injection of malonate. MK-801, however, was effective against intrastriatal malonate. Acute systemic 3-NP resulted in neuronal damage and cytoskeletal disruption in the CA1 region of the hippocampal formation, including an extensive loss of MAP2 immuno-reactivity, but sparing of τ. The neuronal loss in CA1 was delayed as compared to striatum. Chronic intraventricular infusion of 3-NP produced a different pattern of neuronal damage. Loss of τ-1 immuno-reactivity was observed in CA3 and CA1 s. oriens, whereas MAP2 immunostaining was preserved. These results demonstrate that chronic and acute administration of metabolic inhibitors produce distinct patterns of neuronal damage and cytoskeletal disruption. The results further suggest a differential involvement of the NMDA receptor in malonate-induced neuronal damage in striatum as compared to the hippocampus. The pattern of neuronal damage and cytoskeletal disruption observed following acute metabolic impairment resembled some aspects of neurofibrillary pathology in AD, but did not result in τ hyperphosphorylation.  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号